S. R. Pattanaik
BACKGROUND The aim of this study was to evaluate the efficacy and safety of empagliflozin as an add-on drug in type 2 diabetes mellitus (T2DM) patients demonstrating inadequate disease control to triple drug treatment of glimepiride, metformin and teneligliptin. MATERIALS AND METHODS The prospective, observational study, conducted in a clinical setting, included subjects with T2DM, aged between 40-70 years, with inadequate disease control to triple drug treatment (glimepiride, metformin and teneligliptin) and glycated haemoglobin (HbA1c) of >7.5%. Clinical parameters such as serum creatinine, urea, HbA1c, fasting and postprandial blood sugar levels, and weight was measured before and after the study. The pre-and post- anthropometric and laboratory parameters were compared using paired t-test and Wilcoxon signed-rank test. RESULTS The study included 41 subjects with a mean age and disease duration of 58±5.13 years and 5±2.10 years respectively. Fasting and postprandial blood sugar levels, weight and HbA1c% of the subjects following treatment showed significant (P <0.0001) improvement from the pre-treatment values. The HbA1c% was <0.7% in 46.34% (n=19) of the subjects, and 53.66% (n=22) of the subjects achieved HbA1c >0.7% reduction. Adverse reactions noted in the subjects included mild hypoglycaemia, urinary tract infection and mycotic infection. CONCLUSION Empagliflozin can provide significant clinical benefits for T2DM patients, showing inadequate control to triple drug treatment of metformin, glimepiride and teneligliptin.
